Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) has entered into a non-binding letter of intent to acquire all outstanding shares of Quantum.IQ, a Vancouver-based AI-driven quantum cybersecurity company. The proposed transaction, which involves issuing up to 14 million Redwood common shares subject to milestone-based consideration and a staged escrow release over 24 months, is intended to enhance Redwood’s presence in the emerging field of quantum-safe security.
Quantum.IQ focuses on helping organizations—particularly in government, defense, financial services, and critical infrastructure—prepare for quantum-enabled cyber threats. Its post-quantum cryptography platform assesses cryptographic vulnerabilities, plans migration to quantum-resistant systems, and monitors ongoing cybersecurity readiness. The acquisition would add these capabilities to Redwood’s existing portfolio, which centers on using artificial intelligence to accelerate chemistry research and development, including drug discovery and defense solutions.
Redwood CEO stated that the addition of Quantum.IQ could significantly expand the company’s cryptographic intelligence and quantum-readiness assessment offerings, complementing its broader AI and advanced computational technology focus. The acquisition remains subject to due diligence, definitive agreements, regulatory approvals, and other customary closing conditions.
For more details on the announcement, visit the full press release at https://ibn.fm/D0lb6. Additional information about Redwood AI Corp. is available at https://redwoodai.com/.
This move comes as quantum computing advances pose increasing risks to current encryption standards. By integrating Quantum.IQ’s technology, Redwood aims to offer proactive solutions for organizations transitioning to quantum-resistant security frameworks. The deal underscores the growing importance of post-quantum cryptography in safeguarding sensitive data against future threats.
Redwood AI Corp. trades on the Canadian Securities Exchange under the symbol AIRX, on the OTCQB under RDWCF, and on the Frankfurt Stock Exchange under Y0N. The company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up, with a platform designed to enable faster development of new therapies and chemistry-driven applications.